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ABSTRACT OF THESIS

DETERMING THE EFFECTS OF CD151 AND β1 ON TUMOR CELL
ADHESION
Previous studies have shown that the upregulation of CD151 and β1 is associated with
poor prognosis in many cancers such as breast cancer. Studies have provided evidence
that these proteins are associated with the adhesion and migration of tumor cells. In this
study, a microfluidic flow chamber was utilized to determine how CD151 and β1 affected
the firm and initial adhesion of metastatic breast cancer cells to a planar endothelial
monolayer under shear stress. This system mimicked the adhesion of metastatic breast
cancer cells to the endothelial cells of the circulatory system. CD151 and β1 increased the
firm adhesion of metastatic breast cancer cells onto an endothelial monolayer when
subjected to high shear stresses. CD151 and β1 increased the initial adhesion of metastatic
breast cancer cells onto an endothelial monolayer. A transwell assay was utilized to
determine how CD151 and β1 affected random migration through different matrixes and
random transendothelial migration. CD151 and β1 decreased the random migration of
metastatic breast cancer cells through matrices. Additionally, background information is
provided related to the metastatic cascade, how it can be modeled with microfluidics, and
how CD151 and β1 have been known to effect cancer and metastasis.
KEYWORKDS: metastasis, microfluidics, tumor cell adhesion, transwell assay, MDAMB-231 metastatic breast cancer cells, HUVEC endothelial cells
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Chapter 1: Introduction
Despite the fact that Richard Nixon declared the war on cancer in 1971, cancer remains to
be one of the leading causes of death. In particular, cancer metastasis remains poorly
understood[1]. One important aspect of understanding the metastatic cascade is to
identify key surface proteins that are involved in the process. In the past decades, CD151
and β1 shown to be upregulated in many cancer types such as breast, lung, and prostate
and have been correlated with poor prognosis[2, 3]. However, how these proteins affect
metastasis remains poorly understood[4-7]
This is due to the use of animal models and traditional models that do not mimic the
physiological conditions in humans. In recent years, microfluidic models have been
utilized to mimic the conditions of the human body. These models implement human
cells while maintaining shear that physiologically representative unlike traditional
models[8].
In the studies described here, a microfluidic flow chamber produced by Ibidi was utilized
to study the adhesion of breast cancer cells to an endothelial monolayer. To study random
migration, a Boyden chamber, more commonly known as a transwell assay, was utilized.
The specific objects here were:
1) To determine if CD151 and β1 decrease the firm adhesion of metastatic breast
cancer cells onto an endothelial monolayer
2) To determine if CD151 and β1 decrease the initial adhesion of metastatic breast
cancer cells to an endothelial monolayer.
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3) To determine how CD151 and β1 affect the random migration of metastatic breast
cancer cells through either gelatin or basement membrane extract both when a
endothelial monolayer was present or absent.
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Chapter 2: Background
2-1 The Metastatic Cascade
While cancer is the second leading cause of death in the United States, only ten percent
of those deaths are caused by the primary tumor[9, 10]. The remaining ninety percent is
caused by secondary metastases which are difficult to treat and detect [10, 11]. These
secondary tumors are formed after a tumor cell has undergone the metastatic cascade
which can be viewed in Figure 2-1. The first step in the metastatic cascade is the process
of angiogenesis which is the vascularization of a tumor which is triggered by the
upregulation of angiogenic factors and the down regulation of inhibitors of vessel
growth[4, 12]. The tumor can be avascular for many years at which time it does not grow
beyond a millimeter in diameter nor do metastases occur. However, once vascularization
occurs, the tumor can grow quickly in size because it now has necessary nutrients and
oxygen, and the tumor cells increase their ability to metastasize because of the close
proximity to the vascular[13-15]. Evidence of angiogensis’ role in metastasis can be
found in studies that demonstrate that the occurrence of metastases in distant sites is
correlated with the count of microvessels. In these studies, 49 patients with invasive
breast carcinoma had specimen removed, and it was found that with each 10-microvessel
increase in the 200 x field, there was a 1.59-fold increase in the chance of metastasis
occurring. Once the vessel count exceeded 100 in the 200 x field, 100 percent of patients
had secondary metastases[16]. It is also hypothesized that the release of degenerative
enzymes during angiogenesis aids the escape of cancer cells from the primary tumor[15,
16].
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The next step in the metastatic cascade is the tumor cell undergoing the epithelial to
mesenchymal transition (EMT) in which the tumor cell will transition from an epithelial
cell to a mesenchymal type cell[4]. There are three instances in which a cell can undergo
the EMT. The first is during implantation, embryogenesis, and the development of organs
in a fetus. The second is associated with tissue regeneration and organ fibrosis. The final
instance is associated with cancer progression and metastasis. It is believed that EMTinducing signals such as HGF, EGF, and TGF-β are responsible for the induction and
activation of a series of transcription factors that control the EMT program[17]. The loss
of E-cadherin in particular is vital to the process and leads to dramatic changes in the
cells including a loss of intercellular adhesion ability which allows for detachment from
the primary tumor, and the morphological change to a motile phenotype. The expression
of matrix metalloproteinase during this transition aid in the digestion of laminin and
collagen IV which are key components in the basement membrane. Changes to the matrix
will then trigger a positive feedback loop which enhances a cell’s ability to proliferate
and invade the matrix[4].
After a tumor cell undergoes the EMT and detaches from the primary tumor, it can
migrate to the vasculature where it can enter through the process of intravasation. After
the cell intravasates, the tumor cell can circulate throughout the body. How a secondary
site is located can be explained by two hypotheses. The first is the seed and soil
hypothesis which was introduced by Paget in 1889. This hypothesis compares the tumor
cell to a seed and the secondary site to the soil. He proposed that tumor cells preferred
microenvironments in which they were most compatible in. He analyzed over 900
autopsy records of cancer patients to justify this hypothesis. Forty years after the
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introduction of the seed and soil hypothesis, Ewing proposed the mechanical hypothesis
which states that the secondary site is selected when a tumor cell reaches a site in the
vascular that diameter is smaller than the diameter of the cell. This process of getting
lodged in the vasculature is physical occlusion. In the 1970s, research was performed
showing that secondary sites are selected by a combination of these two events[4, 18]. In
the studies described here, physical occlusion was not taken into account. Rather, the
steps of interest are those that take place when the secondary site is determined by the
seed and soil hypothesis.
If the tumor cell survives the physical stress of the circulatory system, it will come into
contact with the vessel wall at which point it will start rolling on the wall. This will occur
in vessels with a diameter larger than the diameter of the tumor cell. The tumor cell can
interact with the endothelial cells that compose the lining of the vasculature, and the
tumor cell can adhere to an endothelial cell. This cell’s ability to adhere will depend on a
variety of factors including the resident time which is depended on the shear force
exercised on the cell and the adhesive forces on the ligand-receptor pairs between the
cells. It is also depended on the frequency of the cell colliding with the membrane-bound
receptors and the endothelial ligands[4].
The next step in the metastatic cascade is extravasation which is the rate limiting
step[19]. In this step, the cancer cell migrates through the endothelial lining of the vessel
and penetrates the supporting extracellular matrix. It is widely believed that the CXCchemokine ligand 12 (CXCL12) is associated with extravasation. This chemokine is
secreted by stromal cells in distant organs and attract cells with the CXCR4 and CXCR7
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receptors[20]. However, the complete mechanism of extravasation remains relatively not
understood.
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Figure 2-1: The steps of the metastatic cascade. A.) First, angiogenesis, or the
vascularization of the tumor must occur. B) Angiogensis is followed by EMT and
detachment from primary tumor. C.) After detachment, the tumor cell can then
invade the circulatory system by a process called intravasation. D.)The tumor cell
will then circulate in vasculature. E.) Once contact has been made, the tumor cell
can then adhere to vessel wall. F.) After the tumor cell has adhered, it will then
migrate through the endothelial monolayer and penetrate the supporting matrix
through a process called extravasation. G.) After exiting the vasculature, a tumor
cell can form a secondary tumor.
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2-2 Microfluidic Models
2-2.1 Pitfalls of Traditional Models
The main reason that the metastatic cascade is still poorly understood is because of the
models that have been utilized to study it. Traditional in vivo models such as rat and
mouse models have poor imaging capabilities which makes it impossible to determine if
tumor cell adhesion or tumor cell extravasation is the step that is being mainly effected
by the protein or chemoattractant of interest because it is impossible to visualize the
arrest of the tumor cell on the endothelial lining[20, 21]. An alternative to the tradition rat
and mouse model is using a zebrafish whose endothelium are transparent. However, it is
still impossible to preform tightly controlled parametric studies. It is also impossible to
directly relate the effects to humans because the endothelial cells composing the vessels
are not human cells, and therefore, the surface expression of proteins is not identical to
that seen in humans. This leads to different tumor-endothelial cell interactions than those
in humans[8, 20].
The most common in vitro studies are static well plate studies. For adhesion studies,
endothelial cells would be seeded into the wells and allowed to grow to confluence. Then,
the endothelial cells are stimulated to express adhesion molecules before cancer cells are
allowed to settle on the endothelial cells. After a given settling time, the cells are then
subjected to shear through a series of washes[22, 23]. The problems with this assay is that
the shear from the washes would not be physiologically representative, constant, known,
nor consistent[23, 24]. It is also impossible to view the cells undergoing detachment[23,
25]. Finally, only firm adhesion can be examined[25].
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To adapt a well plate in order to study migration and extravasation, transwell inserts, also
known as a Boyden chamber, are added. These are inserts that have a membrane on the
bottom. Endothelial cells can be grown directly on the membrane or the membrane can
be coated with a matrix such as Basement Membrane Extract onto which endothelial cells
can be seeded. Cancer cells are then placed in the transwell, and a chemoattractant in the
bottom of the chamber. The number of cancer cells that migrate through the membrane to
the bottom of the well can then be counted[20, 26]. However, it is impossible to tightlyregulate the local micro-environment nor can studies be performed under flow[27, 28].
Finally, the Boyden chamber only allows extravasation to be visualized in a plane parallel
to the endothelial monolayer making it impossible to visualize the cell to cell
interactions[27, 29]. While these studies help understand trends in extravasation, these
limitations must be kept in mind when they are being utilized.
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A.

B.

C.

Figure 2-2: Common models to study metastasis. A.) Tail vein injections into mouse
and rat models. B.) Static well plate studies in which cancer cells are allowed to
adhere to the monolayer. C.) Transwell assays in which cancer cells are allowed to
migrate through the endothelial monolayer into a bottom chamber.
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2-2.2 Benefits of Microfluidic Models
In recent years, microfluidic models have been utilized to address many of these
concerns. The assay that inspired the design of the earliest microfluidic models was the
parallel plate flow chamber which was introduced in 1987[30]. This system, which can
be viewed in Figure 2-3(a), was novel because it could be connected to a pump which
would provide a stable and known shear making much more representative of the
physiological conditions than traditional static studies. It consisted of a permanox slide
which endothelial cells were grown on, a silastic gasket which separated the slide from
the base, and two polycarbonate bases. One of the bases had an entry and an exit that
connected to a flow system.
In 2000, Moss et al. preformed work utilizing a parallel plate flow chamber to study the
initial adhesion of breast cancer cells to an endothelial monolayer. Flow studies were
performed in which cancer cells were flowed into the chamber and their ability to adhere
to the monolayer was examined. Studies were performed in which the monolayer was
stimulated with TNF-α which were compared to studies without stimulation. The two
shear stresses chosen for studies was 0.25 and 1.0 dyne/cm2. The maximum amount of
adhesion occurred at 0.25 dyne/cm2 with a stimulated monolayer, and no adhesion was
viewed at 1.0 dyne/cm2 without stimulation[31].
Moss et al. continued their work on adhesion by examining initial attachment versus firm
attachment. For these studies, a metastatic and nonmetastatic breast cancer cell line were
compared. For the initial adhesion studies, it was found that only at high shear stresses is
do metastatic cells adhere more to the endothelial monolayer. For studies in which firm
attachment was examined, there was no difference in detachment from the monolayer
11

except at 5 dyne/cm2 where the metastatic cells were more adherent, and at 10 dyne/cm2
where the nonmetastatic cancer cells were more adherent[25].
However, with the invention of microfabrication technology such as photolithography,
micro-scale flow chambers were able to be produced. These micro-scale, called
microfluidic, flow chambers were better able to reproduce physiological conditions, and
they required less resources due to their small size[32].
Examples of commercially produced microfluidic flow chambers are those produced by
Ibidi. One of special interest is the Ibidi μ-Slide VI0.4 which can be viewed in Figure 23(b). Each slide contains six channels for flow experiments. The ability to perform
multiple experiments on a single slide makes it more resource friendly than the parallel
plate flow chamber in which only one study could be performed per permanox slide.
Each slide is sterile and treated with a cell culture coating which increases the
consistency of the experiments. As can be seen in the comparison in Figure 2-3, unlike
the parallel plate flow chamber, the Ibidi slide is also a single piece so the height of the
chamber will be constant and there is no possibility of leakage.
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A.
Polycarbonate Base
Permanox Slide
Silastic Gasket

Polycarbonate Base

B.
17 mm

Ibidi

3.8
mm

Figure 2-3: Comparison of a parallel plate flow chamber (A.) and the Ibidi μ-slide
VI0.4 (B.).
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2-2.3 Determining Shear Stress in a Microfluidic Flow Chamber
Shear force is defined by de Nevers as the force which tends to make one surface slide
parallel to an adjacent force. To determine the shear stress on the surface, the force is
divided by the area that is in contact as shown in Equation 1. While solids can resist these
shear forces, fluids cannot. Once subject to a shear force, a fluid will move and keep
moving as long as the force is applied.
𝜏=

𝐹
𝐴

(1)

For Newtonian fluids, the shear stress can be described by Equation 2 which is Newton’s
law of viscosity. This law states that the shear stress, 𝜏, is linearly proportional to the
velocity gradient which is represented by

𝜕𝑢
𝜕𝑦

. The slope of the line is the dynamic

viscosity 𝜇. Fluids that do not follow this behavior are non-Newtonian fluids[33].
𝜏=𝜇

𝜕𝑢
𝜕𝑦

(2)

The shear stress through a vessel that is inelastic, cylindrical, and straight can be
computed by the Haagen-Posseuille equation in which 𝑄 is the volumetric flowrate and 𝑑
is the diameter of the vessel. The Haagen-Posseuille equation is Equation 3[34].
𝜏 = 32𝜇

𝑄
𝜋𝑑3

(3)

The channel in the Ibidi μ-slide is rectangular rather than cylindrical. Therefore, a
hydrolic radius must be used. The hydraulic radius is allows a noncircular channel to be
approximated as a cylindrical channel. The equation for the hydraulic radius is shown in
Equation 4[33].
14

𝐻𝑅 =

(𝑎𝑟𝑒𝑎 𝑝𝑒𝑟𝑝𝑒𝑛𝑑𝑖𝑢𝑐𝑢𝑙𝑎𝑟 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑙𝑜𝑤)
⁄(𝑤𝑒𝑡𝑡𝑒𝑑 𝑝𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟)

(4)

Ibidi provided the equation used to calculate shear stress through the channel of the Ibidi
μ-slide which is shown in Equation 5. The constant includes the hydraulic radius. The
dynamic viscosity, 𝜇, must be in the units of

𝑑𝑦𝑛𝑒∙𝑠
𝑐𝑚2

and the flow rate, 𝑄, must in in the

units of mL/min. The resulting shear stress is in the units of dyne/cm2.
(5)

𝜏 = 176.1𝜇𝑄
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2-3 CD151 and Cancer
CD151 is a member of the tetraspanin family of proteins. These proteins are named for
the fact that they contain four transmembrane domains. In addition to these
transmembrane domains, their structure contains a short extracellular and an intracellular
loop and a large extracellular loop. This large extracellular loop contains three α-helices
and a variable region which contains protein-protein interaction sites. This protein can be
viewed in Figure 2-4. Tetraspanins regulate a variety of cell functions including
morphology, motility, and invasion[2]. In humans, CD151 is expressed by a variety of
cells including nearly all epithelial, endothelial, and fibroblastic cells[35]. Its importance
can be demonstrated that if a mutation of the gene for CD151 occurs, the result is a
variety of disorders including a skin blistering disease, kidney disruption, and
sensorineural deafness[36].
CD151 was the first tetraspanin that was associated with cancer, and since this discovery,
it has been found to participate in almost all stages of cancer progression and the
formation of metastases[37, 38]. Its upregulation has been associated with many cancer
types including breast, lung, endometrial, and prostate[5-7, 39, 40]. This upregulation is
correlated with a poor prognosis[38]. One potential reason that CD151 could play a major
role in progression of cancer is because it associates tightly with the integrins α3β1, α6β1,
α6β4, and α7β1 which interact with laminin, a key component of the extracellular matrix.
This interaction also allows CD151 to modulate integrin-dependent functions of the cell
such as migration, signaling, and adhesion strengthening all of which play roles in the
progression of cancer[2].
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Yue et al. performed in vivo assays with BDX rats , a variation of the albino rat, in which
the rats were injected with 1x106 tumor cells. While when both control ASML, a highly
metastatic mouse cancer cell line, and ASML-CD151 kd cells were injected thousands of
metastasis formed, there was a delayed metastatic growth of ASML-CD151 kd cells
compared to the controls in the lymph nodes. This indicates that CD151 is not required
for the formation of metastases but increase the tumor cell’s efficiency to reach the lymph
nodes since the CD151 kd cell line reached the lymph nodes but at slower rate. In studies
in which the adhesion to different matrices was examined, the ASML-CD151 kd cell line
did not differ in matrix protein adhesion compared to the control ASML cell line. The
ASML-CD151 kd cell line also did not differ in migration through a transwell
membrane[41].
Studies performed by Yang et al. demonstrated that CD151 affects the ability of a
mammary cell to invade and its motility in both nonmetastatic MCF-10A and MDA-MB231 cell lines[5]. Mobilization of cells into a gap was examined by scratching a gap in a
confluent cell monolayer and observing how the cancer cells invaded the gap. For both
cell lines the absence of CD151 reduced the mobilization by nearly 50%. CD151’s effect
of invasion through a transwell insert was also examined. There was a 78% reduction in
invasion for the MDA-MB-231 CD151 kd cell line. There was also a significant
reduction in invasion for the J110 (a malignant mouse breast cancer) CD151 kd cell line.
Showing that when CD151 is absent, there is an overall reduction in invasion for both
cell lines. This study also indicated that CD151 kd MDA-MB-231 cells had a decreased
ability to spread on laminin-1 when the α6 integrin was blocked and the cells were not
stimulated with EGF. CD151 ablation was not shown to effect spreading on fibronectin.
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EGF, phorbol 12-myristate 13-acetate (PMA), nor could insulin-like growth factor I
overcome CD151 ablation in invasion or spreading. In vivo studies performed on nude
mice, in which control MDA-MB-231 cells where injected and the cells expressed either
shRNA (small hairpin RNA) or CD151 shRNA, Tumors expressing the control were
detected at 8 to 9 weeks while the CD151 ablated cells did not appear until 11 to 12
weeks. Tumor growth was also delayed when tumor cells were injected into mammary fat
pads. There was no morphologic differences between the tumors formed[5].
Takeda et al. examined how CD151 affected the first stage of metastasis which is
angiogenesis[42]. Studies in which an aoritic ring was embedded into Matrigel showed
that aortic rings from CD151-null mice had impaired microvascular sprouting by 35%
after 4 days. Similarly, matrigel plugs that were implanted into CD151-null mice showed
diminished vascularization after 7 days. When CD151-null mice were injected with
Lewis lung carcinoma, LLC, cells, smaller solid tumors formed compared to the wild
type mice. There was also a significant decrease in microvessel density. When a corneal
micropocket assay was performed, the corneal vessels from CD151-null mice showed
minimal bFGF-stimulated sprouting.
In vitro studies showed that there was no significant difference between mouse lung
endothelial cells, MLECs, ability to proliferate or adhere when derived from CD151-null
or wild type mice. However, several cell functions were altered. The CD151-null cells
had decreased spreading on Matrigel by 50 % and to a lesser extent on fibronectin and
gelatin. The transwell migration of CD151-null MLECs toward bFGF (basic fibroblastic
growth factor) was reduced when the wells were coated with Matrigel or gelatin, but
there was not a reduction when fibronetin was the coating. Invasion through Matrigel was
18

also diminished by 50 % for the CD151-null MLECs. The CD151-null MLECs also had a
diminished ability to grow cellular cables, and CD151-null MLEC spheroids had
significantly shorter capliary0like sprouts than the wild type. These results allowed
Takeda et al. to conclude that CD151 plays a critical role during angiogenesis[42].
Takeda et al. continued their work on CD151 and metastasis by examining how
metastasis occurred in CD15- null mice[43]. The murine cancer cell lines, B16F10, a
melanoma cell line, and LLC were used for these experiments. For in vivo experiments,
B16F10 cells were injected into the tail veins, and there were fewer metastatic foci in the
lungs of the CD151-null mice compared to the wild type after two weeks. The
experiments were repeated with LLC cells, and the results were the same. The CD151null mice also had fewer metastases in the kidneys, peritoneum, and the ovaries. Size
distributions were not different between the two genotypes. Further studies were
performed where the number of metastases was counted at 6, 24, 48, and 72 hours. Fewer
B16F10 cells were recovered from the CD151-null mice at all points. Blood was
analyzed to determine if there was a rapid clearance in the CD151-null mice, and the
percentage of B16F10 cells was not diminished in the blood of the CD151-null mice at
48 or 72 hours. CD151-null mice did not differ in leukocyte engagement or did not show
an increased tendency to undergo cell death.
Takeda et al. also did a series of adhesion and transwell assays using MLECs derived
from CD151-null mice or wild type mice. The B16F10 cells adhered significantly less to
the monolayers of MLECs derived from the CD151-null mice both with and without the
addition of TNF-α. The MLECS were grown on a matrix before being removed, and the
cancer’s cell’s ability to adhere to this matrix was examined. B16F10 cells adhered
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significantly less to the ECM derived from the CD151-null mice that suggests that the
CD151-null endothelial cells create a deficiency in the ECM. Transwell studies showed
that transendothelial migration of B26F10 cells through a monolayer of CD151-null
endothelial cells was diminished. When migration of B26F10 cells through a monolayer
of keratinocytes, there was no significant difference between the wild type and the
CD151-null mice indicating that the effects of CD151 ablation differs between cell
lines[43].
Zijilstra et al. examined how the anti-CD151 antibody, mAB 1A5, affected intravasation
and metastasis[38]. To determine if CD151 effected spontaneous metastasis, a chick
embryo spontaneous metastasis assay was utilized. These animals contained either HEp3
or HT1080 tumors, and were injected with mAB 1A5 or the control antibody mAb 29-7.
The anti-CD151 antibody could inhibit spontaneous metastasis. Depsite HT1080 and
HEp3 having different CD151 expression, the mAB 1A5 inhibited spontaneous
metastasis in both. Experiments using SCID mice had similar results. This indicated that
CD151 inhabitation occurred independently of tumor expression.
Next, the migration of HEp3 cells through a matrix was examined. The mAB 1A5
antibody inhibited migration through laminin. However, the antibody also reduced the
level of migration through collagen and uncoated filters. It was suggested that the
antibody enhanced the matrix interactions. To examine if CD151 effected extravasation
and the subsequent formation of secondary tumors, the CAM model was used. HEp3
cells in the presence and absence of mAb 1A5 adhered to the vasculature. Those not
treated with the mAB 1A5 antibody disseminated throughout the CAM stroma. However,
those treated with mAb 1A5 proliferated but failed to disseminate which suggested to
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Zijilstra et al. that the antibody was preventing migration. In vivo studies in which HEp3
cells were injected i.v. in the presence of the control or the anti-CD151 antibody showed
that mAb 1A5 did not inhibit tumor cell arrest or growth as there were tumor cells found
in the LCAM and the lung after four days for both treatments. This indicates that the
inhibition of migration plays a greater role in migration from the primary site than in the
migration to the secondary site. When HEp3 or HT1080cells were injected into the CAM
model, the animals that had been treated with mAB 1A5 had tumors with a defined
boarder and little to no invasion of the surrounding stroma compared to the control
animals that had an irregular invasive front on the tumor-stromal interface. When HEp3
tumors were implanted into the CAM, it was found that mAB 1A5 inhibited migration
velocity, but there was residual movement and the cells’ ability to change direction was
unaffected. This inhibition was shown to be caused by the rear of the tumor cell not being
able to detach. However, when CD151 was silenced with shRNA silencing, neither the
migration nor metastasis was limited significantly. Further experiments using the CAM
model showed that CD151 inhibition prevented intravasation which inhibits the
subsequent metastasis[38].
Deng et al. examined the effects of CD151 on transendothelial migration and migration
through Matrigel[44]. The tumor cell line MCF-10A was the cancer cell line and Human
Umbilical Vein Endothelial cells were chosen as the endothelial cell line. When no
chemoattractant was present, there was no statistical difference in transendothelial
migration between the knock down cell line and the control. The same was true when
TGF-β was utilized as a chemoattractant. However, when stimulated with EGF, the
CD151 knock down cell lines had a reduced migration by 50%. When this study was
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repeated to examine the effects of migration through Matrigel, CD151 knock down cells
migrated less when stimulated with EGF[45].
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Figure 2-4: The tetraspanin CD151. The name tetraspanin is derived from the four
extracellular regions. There are also three loops- a short intera and extracellular
loops and one large extracellular loop.
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2-4 β1 and Cancer
β1 is a member of the integrin family which are heterodimeric cell surface receptors. Each
integrin consists of an α and a β subunit that are non-covalently bound[46, 47]. These
subunits are transmembrane glycoproteins with large globular amino-terminal
extracellular domains that bind to form an ellipsoidal head as can be viewed in Figure 25[47]. There are eight different β subunits and 18 different α subunits which interact to
form at least 22 different integrins with 10 of these containing β1[46, 48]. The primary
function of β1 is to bind to laminin, but it can also interact with many of the other
components of the extracellular matrix such as type IV and V collagen and
fibronectin[47, 49]. This suggests that β1 potentially plays a large role in extravasation
since a key step in extravasation is the tumor cell penetrating the extracellular matrix[4].
There have been examples in literature of β1 effecting metastasis. One study performed
by Fijita et al. examined the effects of β1 on the invasion and metastasis of colorectal
cancer. A total of 51 tissue samples of tumors and normal mucosa were acquired during
surgeries and analyzed using an immunoblot assay. Of these samples, the pre-β-unit was
increased in 15 samples, and β1 was increased in two of the samples. Fifteen of these
cases with altered expression had lymph node metastases while only 12 of the samples
with unaltered expression had lymph node metastases suggesting that β1 expression plays
a key role in the metastasis of colorectal cancer to the lymph nodes[50].
A second study was performed by Elliott et al. which utilized a murine model to
determine how the Anti-β1 integrin IgG affected pulmonary macrometastases. One of two
spontaneous intraductal mammary adenocarcinoma cell lines was injected into the
mammary fat pad of the animals. The first cell line was SP1 and the second was its
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metastatic sister line SP1-3M. Either the Anti-β1 antibody IgG or the control non-immune
IgG was injected every two days. The Anti-β1 antibody suppressed the growth of overt
macrometastases in the SP1 cell line with a significant reduction in the mean diameter of
the nodules compared to the control group. However, metastatic tumors still formed
suggesting that the β1 antibody impeded the formation of metastases after extravasation
occurred[51].
Cannistra et al. examined how β1 affected ovarian cancer. Flow cytometry showed that
the β1 chain was widely expressed in the four ovarian cancer cell lines, CAOV-3, SKOV3, OVCAR-3, and SW626, that they were examining. When tumor samples were
harvested from nine patients, all samples expressed the β1 chain. Adhesion studies were
performed in which the cancer cells’ ability to adhere to different matrixes was tested. All
cell lines had significant binding to collagen type I. The CAOV-3 and the SKOV-3 cells
bound significantly to laminin and fibronectin. The OVCAR- and SW626 cells bound to
laminin and fibronectin to a lesser extent. To determine who β1 affected these cells ability
to adhere to the matrix, the 4B4 anti-β1 antibody was utilized. Binding of CAOV-3 cells
to collagen was inhibited by the antibody. Binding to laminin was prevented by the antiβ1 antibody, but not by antibodies for α2 or α6 which indicates that laminin binding is
facilitated by β1. No inhibitory effect was observed when the cells bound to fibronectin.
To determine if β1 was responsible for the binding of cancer cells to the peritoneal
mesothelium, adhesion of CAOV-3 cells to confluent monolayers of mesothelial cells
was examined when both the anti-β1 antibody was present or absent. The binding was not
inhibited by the presence of the antibody suggesting that more than the β1 integrin effects
the metastasis of ovarian cancer[52].
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Canninstra continued studying the effects of β1on ovarian cancer with Strobel. In these
studies, the ovarian cancer cell lines 36M2, CAOV-3, and SKOV-3 were utilized. All of
these cell lines widely expressed the β1 integrin. For these studies, the 4B4 and the
MAB13 anti-β1 antibodies were utilized. As in the previous study, there was a minimal
inhibitory effect of the 4B4 antibody on the binding of cancer cell lines to confluent
monolayers of peritoneal mesothelial cells even at high concentrations of the 4B4
antibody. However, when the MAB13 antibody was utilized, the binding was inhibited
significantly in all cell lines. This suggests that the inhibitory effect is dependent on type
of antibody used. The studies in which CAOV-3 ability to bind to fibronectin were
repeated with both of the antibodies. The MAB13 antibody inhibited the binding of the
CAOV-3 to a greater degree than the 4B4 antibody. When the cells were exposed to the
RAT16 α5-integrin antibody, the binding of 36M2 and CAOV-3 to the mesothelium was
inhibited suggesting that the α5β1 integrin is responsible for the binding of ovarian cancer
to the mesothelium[53].
Michelle Chen presented a poster in which the role of β1 in extravasation was examined.
Here, when β1 was silenced in MDA-MB-231 cells, extravasation was reduced. It was
determined to be partially caused by a reduced adhesion rate to the monolayer which was
confirmed with flow studies on a planar monolayer[54].
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α subunit

β1

Figure 2-5: A integrin containing the β1 subunit. The α unit and the β1 are
transmembrane proteins that bind noncovalently to form an ellipsoidal head.
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2-5 Mechanisms of Tumor Cell Adhesion and Migration
Cell migration is allowed through a combination of adhesion, protrusion, and contraction.
Adhesion forces are present at both the leading edge and the rear of the cell. There is an
optimum amount of adhesive forces that allows for the fastest migration. This was
demonstrated in a study by Gupton and Waterman-Storer in which epithelial cells were
seeded on varying concentration of fibronectin. On low concentrations of fibronectin, the
cells had few but dynamic adhesions. On high concentrations of fibroneticin, the cells
had many but less dynamic adhesions. On medium concentrations, there were moderate
adhesions with well-organized dynamic patterns of actin flow which gave rise to the
highest migration rates. This trend can be viewed in Figure 2-6[55].
Adhesion at the leading edge of the cell provides traction for the cell as protrusions form
and also initiates signals that are responsible for the dynamics of migrations[56]. This is
caused by the polarization of the cell due to external signals and results in the extension
of a protrusion from the leading edge which is thought be caused by vesicle trafficking of
adhesive molecules to the leading edge[56, 57]. The adhesive forces in the cell must be
balanced appropriately. If the adhesive forces at the leading edge of the cell are too weak,
the cell cannot pull forward. If the adhesive forces at the rear edge of the cell are too
strong, the cell cannot detach from the substrate and move forward[58].
Contractile forces caused by myosin motors work to help break adhesive interactions by
the application of physical stress. Studies using fibroblasts suggest that during this
process of the rear release, the majority of integrins are left on the substrate suggesting
that these integrins play a major role in the attachment and detachment of the rear of the
cell. Integrins can also be removed from the rear end of the cell by endocytosis. Once
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endocytosis has occurred, the integrins can either accumulate in the cell or are transported
to the cell front. This process is called integrin trafficking[57].
Evidence has suggested that there are multiple pathways for β1 endocytosis. One such
pathway is regulated by the AP-2 clathrin adaptor. This pathway involves the binding of
AP-2 to the cytoplasmic tail of CD151 which associates with the integrin β1. The clathrin
mediated pathway also includes the cargo-specific endocytic adaptor Numb which binds
directly to the β integrin sub-units and interacts with components of the clathrin
endocytic mechanism. There are also pathways which are not mediated by clarthrin.
Examples of these pathways include the internalization of α2β1 mediated by PKC and
caveolae and the internalization of αLβ1 through a cholesterol-sensitive pathway. These
pathways are modeled in Figure 2-7[59].
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migration

adhesion
Figure 2-6: Trend in how adhesion strength to the substrate effects random
migration. There is an optimum adhesion strength in which the migration is the
fastest.
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Figure 2-7: The different pathways in which integrin can be endocytosed during
integrin trafficking.
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2-6 Interaction of CD151 and β1
As stated previously, CD151 tightly associates with the laminin binding integrins. To
support this, one of the laminin binding integrins, α3β1, has not been found present in
any tissue or cell in the absence of CD151 association [60, 61]. CD151 forms a stable
complex with this integrin and modulates the ligand-binding affinity of the integrin as
well as shifting the conformational equilibrium position [60, 62, 63]. This complex can
be seen in Figure 2-8. Studies have shown that CD151 and α3β1 will concentrate together
at the leading edge of a migratory cell and at the rear of the cell immediately before
retraction. This suggests that together, they establish front-rear polarity during migration
[64]. It has also been demonstrated that this CD151-α3β1 complex is stable even when
treated with the surfactant Triton X-100[63].
Nishiuchi et al. performed studies to determine how the associate of α3β1 with CD151
effects ligand-binding. Studies in which there was CD151-free integrin α3β1 and CD151bound integrin α3β1 in phosphatidylcholine liposomes were allowed to bind to laminin10/11 surfaces. Less CD151-free α3β1 liposomes bound to the laminin than CD151-bound
α3β1 lipsomes showing that CD151 stabilizes this integrin and increases its potential to
bind to laminin-10/11. To determine how the α3β1 association with CD151 affected the
adhesion of cells, the mAB 8C3 antibody was utilized. This antibody induces dissociation
of CD151 from the α3β1 integrin. When A549 lung carcinoma cells were pretreated with
this antibody, there was less adherence to laminin-10/11 than in untreated cells. Knocking
down the gene for CD151 also decreased adhesion to laminin-10/11. All of these suggests
that CD151 association with α3β1 increases laminin binding[63]. Studies have also
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indicated that the association of CD151 with α3β1 is a factor in the binding to laminin-5
during tumor cell-stromal cell interactions [65].
Integrins, especially β1, interact with CD151 in tetraspanin webs. Tetraspanin webs are
described as assemblies of multimolecular signaling complexes at the cell surface. As the
name suggests, the primary molecules are tetraspanins. However, many other molecules
are included in this web including integrins, membrane receptors, and other signaling
molecules. This web creates a tetraspanin enriched microdomin, TEM. Devbhandari et al.
examined 57 molecules that are found within a tetraspanin web centered on CD151 and
found that β1 had the highest Mascot score and showed that it was the second most
abundant of the tetraspanin partners. In their studies, HCCLM3 cells were utilized
because they had the highest expression of CD151 protein. Using immunofluorescence,
they determined that CD151 and β1 co-localized on the plasma membrane. When CD151
was silenced, the internalization of β1 was impaired which impeded migration. When β1
was silenced in cells with high CD151 expression, the motility and invasiveness was
impaired. However, in cells with low CD151 expression, there was no effect on motility
and invasiveness. It should be noted that the cells with low CD151 expression, the
motility and invasiveness had been low before gene silencing[66].
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Figure 2-8: Association of α3β1 with CD151. This association enhances binding of the
integrin to laminin.
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Chapter 3: Experimental Materials
3-1 Flow System
μ-Slide VI0.4 ibidiTreat: #1.5 polymeter coverslip, tissue culture treated, sterilized (Cat. #
80606) was obtained from Ibidi, USA (Madison, WI). Male lock stopcocks (Cat. # SI30600-04), 1/16 inch hose barb male luer (Cat. # EW-45505-00), and Tygon Lab Tubing,
Non-DEHP, 1/8x3/16 in (Cat. # EW-07407-75) were obtained from ColeParmer (Vernon
Hills, IL). Standard Pump 22 Infusion/Withdraw with standard syringe holder (Cat #.
552226) was obtained from Harvard Apparatus. BD medical 20 mL syringes with leurlok tip (Cat #. BD302830) were obtained from VWR (Radnor, PA).
3-2 Microscope and Camera Assembly for Adhesion Studies
Axiovert 35 inverted microscope, AxioCam MRm (Cat. # 426509-9902-000), and
AxioVision Softer AV 4.9.1 64 bit (Cat. # 4101330906000000) were obtained from Zeiss
(Oberkochen, Germany). X-cite series 120Q was obtained from Exceliates Technologies
(Miamisburg, OH).
3-3 Treatment of HUVEC Cells
3-3.1 HUVEC Culture
HUVEC cells at passage 1 (Cat. # C2519A), EGM-2 SingleQuot Kit Suppl&Growth
Factor (Cat. # CC-4176), EBM Basal Medium Phenol Red Free (Cat. # CC-3129) were
obtained from Lonza (Basel, Switzerland).
3-3.2 HUVEC Subculture
HEPES-Buffered Saline Solution (Cat. # CC-5024), Trypsin Ethylenediaminetetraacid
Acid, Trypsin/EDTA, in a balanced salt solution (Cat. # CC-5012), and Trypsin
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Neutralizing Solution, or TNS, (Cat. # CC-5002) were obtained from Lonza (Basel,
Switzerland).
3-4 Treatment of MDA-MB-231 Cells
3-4.1 MDA-MB-231 Culture
All MDA-MB-231 cell lines were provided by Dr. Xiuvwei Yang (Dept. Pharmacology
& Nutritional Sciences, University of Kentucky). Dulbecco’s Modified Eagle Medium, or
DMEM, with high glucose, no glutamine, no phenol red (Cat # 31053-028) was obtained
from ThermoFisher Scientific (Waltham, MA). This medium was supplemented with
50,000 U of Penicillin Streptomycin, or Pen Strep, (Cat. #: 15140122) and 1mL of
Fungizone Antimycotic (Cat.# 15290-018) to prevent contamination from occurring.
These were obtained from ThermoFisher Scientific (Waltham, MA). The medium
contained 2 mM L-glutamine (Cat. # 21051024) and 1 mM sodium pyruvate (Cat. #
11360-070) which were obtained from ThermoFisher Scientific (Waltham, MA). The
medium was supplemented to a final concentration of 20% with Premium Grade Fetal
Bovine Serum, or FBS, (Cat. # 97068-085) which was obtained from VWR (Radnor,
PA).
3-4.2 MDA-MB-231 Subculture
Trypsin-EDTA (0.25%/0.53 mM) in Hanks Balanced Salt Solution (Cat. # 30-2101) was
obtained from American Type Cell Culture.
3-5 Adhesion Studies
Recombinant Human Tumor Necrosis Factor-alpha, or TNF-α, (Cat. # 210-TA-005) was
obtaind from R&D Systems. Dextran from Leuconostoc mesenteroides (Cat. # D4876)
was obtained from Sigma Aldrich (St. Louis, MO).
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3-6 Staining Cells for Transwell Assay
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate, or DiI stain, (Cat. #
D-282) and 3,3'-Dioctadecyloxacarbocyanine Perchlorate, or DiO, (Cat #. D-275) was
obtained from ThermoFisher Scientific (Waltham, MA).
3-7 Transwell Assay
Corning HTS Transwell-24 well permeable supports (Cat. # CLS3396) and Gelatin from
porcine skin (Cat. #G1890) were obtained from Sigma Aldrich (St. Louis, MO).
PathClear Cultrex Basement Membrane Extract, or BME, (Cat. # 95036-780) was
obtained from VWR (Radnor, PA).
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Chapter 4: Experimental Methods
4-1 Cell Culture
HUVECs were utilized at passages five through eight. The HUVECs were cultured at 37
°C and 5 % CO2 in EGM-2 which was changed every other day at minimum until the
cells were confluent.
Three different variations of the breast carcinoma cell line MDA-MB-231 were utilized.
The control cell line had been transfected with the green florescent protein (GFP) tag to
negate any effect the GFP tag had on adhesion in the kd cell lines. Cell lines of MDAMB-231 with the genes for CD151 and β1 were used as the test cell lines. The gene for
either CD151 or β1 was knocked down using shRNA gene silencing which degrades the
mRNA. This process was performed by Dr. Yang. A GFP tag was used to indicate if the
gene had been successfully knocked down in an individual cell. All cancer cells were
cultured at 37 °C and 5 % in DMEM which was changed every other day a minimum
until cells were confluent.
4-2 Adhesion Studies
4-2.1 Preparation of Endothelial Monolayer
Once the HUVECs reached confluency, the HUVECs were washed with HEPES and
trypsinized. The cell suspension was then neutralized with TNS, spun down, and the
supernatant removed before being resuspended and counted using a cellometer. Cells
were then diluted with EGM-2 to reach the desired concentration, and 30 μL of cell
suspension was seeded into the channels of an Ibidi μ-slide. The seeding density varied
depending on when studies were going to be performed. The HUVECs were allowed to
settle for thirty minutes before the reservoirs of the channels were filled with 60 μL of
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EMG-2. HUVECs were cultured in the Ibidi μ-slide at 37 °C and 5% CO2 until the cells
were confluent at which time, the monolayer was stimulated with 20 ng/mL of TNF-α.
This stimulated important adhesion molecules such as ICAM-1 and PECAM-1. The cells
were incubated with TNF-α for 4 hours before experiments were conducted.
4-2.2 Preparation of Breast Cancer Cells
A confluent flask of cancer cells were trypsinized, spun down, and the supernatant was
removed. The cells were resuspended and counted using a cellometer. The cell
suspension was then diluted to the desired concentration, 5.0 x 105 cells/mL for
attachment experiments and 1.25 x 106 cells/mL for the detachment experiments. The
cells were resuspended in a solution of dextran in EGM-2. The dextran solution had a
concentration of 7.5 g per 100 mL.
4-2.3 Experimental Set Up
One syringe was filled with the cell suspension and a second syringe was filled with the
solution of dextran in EGM-2. For attachment experiments the cell suspension syringe
was connected to the syringe pump while the syringe containing the dextran solution was
connected to the line of tubing through a valve. The tubing before the valve was filled
with the dextran solution while the tubing after the valve leading to the pump was filled
with the cell suspension. This was to minimize the number of cancer cells introduced into
the chamber before flow. This set up was reversed for detachment experiments in which
the tubing before the valve was filled with the cell suspension while the tubing after the
pump was filled with the dextran solution. The tubing was connected to one of the
reservoirs of the Ibidi flow chamber and a second piece of tubing was connected to the
corresponding outlet reservoir. This second piece of tubing led to a waste reservoir. This
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setup can be viewed in Figure 4-1. The flow chamber was placed on top of the stage of
an inverted microscope. The monolayer could be viewed on the desktop computer screen
through use of a camera and the corresponding software. The flow chamber was taped to
the stage to ensure that the same location could be viewed for the entire length of the trial
as shown in Figure 4-2.
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Figure 4-1: Syringe set up for adhesion studies.
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Figure 4-2: Experimental setup for all flow studies.
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4-2.4 Detachment Experiments
To determine how the cancer cells firmly adhere to an endothelial monolayer, detachment
studies were carried out in the Ibidi flow chamber. A suspension of cancer cells at a
concentration of 1.25 x 106 cells/mL were introduced into the chamber through the
secondary syringe. These cancer cells were allowed to settle on the endothelial
monolayer for 30 min. After the cells were allowed to settle, initial bright field and
florescent images were taken. The monolayer was then perfused for 1 minute at a flow
rate of 0.01 mL/min to remove any nonadherent cancer cells, loose endothelial cells, or
cell debris. Bright field and florescent images were taken again after this wash. The
monolayer was then perfused at the flow rate required to produce the required shear of
either 2 or 8 dyne/cm2 [25]. Final bright field and florescent images were taken. The
wash and the 10 minute trial were recorded using the time lapse option on the Axiovision
software. This consisted of the software automatically taking images very second.
4-2.5 Attachment Experiments
To determine how the cancer cells initially adhere to an endothelial monolayer,
attachment studies were carried out in the Ibidi flow chamber. The front end of the line of
tubing was filled with a dextran solution in EGM-2 through use of a secondary syringe
and the primary syringe contained the cell suspension at a density of 5 x 105 cells/mL.
Initial bright field and florescent images of the monolayer were taken. The suspension
was perfused into the chamber at a shear stress of 0.25 dyne/cm2 [25, 31]. Experiments
were conducted for a total of 40 minutes. The trial was recorded using the time lapse
option on the Axiovision software at a frame rate of one frame per second.
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4-3 Random Migration Studies
4-3.1 Matrix Coatings
Six of the twelve transwell membranes were coated with 0.5% gelatin to ensure that cells
would adhere to the membrane. Enough gelatin to coat the membrane was added to the
transwell before being placed in a 37 °C incubator for 2 hours before being allowed to
dry at room temperature overnight[67]. The other six transwells were coated with BME,
which unlike gelatin, contains laminin, the protein to which both CD151 and β1 bind to.
After being thawed on ice, the 20 μL aliquot of BME was diluted with ice-cold sterile
deionized water to 0.125 mg/mL. 150 μL was injected into the transwell before 50 μL
was removed. This step ensured a uniform layer. The transwells were allowed to dry
overnight[68].
4-3.2 Preparation of Endothelial Monolayer
Once the HUVECs reached confluency, the HUVECs were washed with HEPES and
trypsinized. The cell suspension was then neutralized with TNS, spun down, and the
supernatant removed before being resuspended and counted using a cellometer. The cell
suspension was diluted with PBS to a concentration of 1 x 106 cells/mL, and a working
solution of DiI was added to 1 mL of the cell suspension. This cell suspension was
incubated for 20 minutes at 37 °C before being wash three times was EGM-2. Using a
cellometer, the cell suspension was measured, and the suspension was diluted to a
concentration of 5 x 105 cells/mL using EGM-2. 100 μL of cell suspension was added to
tranwell inserts that had been precoated with the matrix. The transwells were placed in an
incubator at 37 °C and 5% CO2 overnight. In the morning, the HUVECs were examined
using a Nikon microscope.
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4-3.3 Seeding of Cancer Cells into Transwells
After checking the HUVECs in the transwells, a confluent flask of cancer cells were
trypsinized, spun down, and the supernatant was removed. The cells were resuspended
and counted using a cellometer. The cell suspension was then diluted to the desired
concentration of 1.0 x 106 cells/mL. For the knocked down cell lines, this concentration
was based off of the GFP transfection rate. For the control cells, 1 mL of suspension was
added to a working solution of diO and the cells were responded in PBS. This cell
suspension was incubated for 20 minutes at 37 °C before being wash three times in
EGM-2. Using a cellometer, the cell suspension was measured, and the suspension was
diluted to a concentration of 1 x 106 cells/mL using EGM-2. For all cell lines, the media
had been removed from the transwell, and 100 μL of cancer cell suspension was added to
each transwell. The transwells were placed in an incubator at 37 °C and 5% CO2 for 24
hours.
4-3.4 Imaging of Transwells
The media was removed from the transwells and the wells before the transwells were
washed twice with PBS. A fixing solution of 3.5% Formaldehyde was prepared, and 100
μL was placed in the transwell, and 600 μL was placed in the well. After 2 minutes, the
formaldehyde solution was removed, and the transwells were washed twice in PBS.
Using a cotton swab, the cells were removed from the apical side of the transwell, and the
transwell was placed on a coverslip. An inverted Nikon microscope was used to image
the transwells. Five representative images were taken-one in the center and one in each
corner. To analyze the images of cells, the NIS Basic Software package was used. The
object count function was used with the intensity option. For all images, the clean option
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was set to x1, and any objects smaller than 5 μm in diameter were assumed to be cell
debris.
4-3.5 Statistical Analysis
A Two-Way ANOVA was utilized to determine the statistical significance of the results.
For all studies, the first condition was cell line. For the flow studies, the second condition
was time while for the transwell assay studies, the second condition was matrix coating
with and without HUVECs. The pairs were compared using the Holm-Sidak method for
pairwise multiple comparison procedures. The analysis was performed using SimgaPlot.
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Chapter 5: Results and Discussion
5-1.Detachment Results
The detachment of the MDA-MB-231 cell lines at 2 dyne/cm2 and 8 dyne/cm2 are shown
in Figure 5-1 and Figure 5-2. When a shear stress of 2 dyne/cm2 is applied to the cells,
there was no difference in the detachment of the cells for the control and the two knock
down cell lines. However, when a shear stress of 8 dyne/cm2 is applied to the cells, the
CD151 kd and the β1 kd MDA-MB-231 cells detach to a greater degree than the control
MDA-MB-231 cells. This indicates that low shear stresses, such as those found in the
venous circulation, the cancer cells can compensate for the lack of CD151 and β1.
However, the cells cannot compensate for the loss of either protein at high shear stresses.
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Figure 5-1: Detachment of MDA-MB-231 cells from an endothelial monolayer when
the monolayer is subjected to a shear stress of 2 dyne/cm2. N=6. Error bars
represent SE. * indicates p-value < 0.05.
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Figure 5-2: Detachment of MDA-MB-231 cells from an endothelial monolayer when
the monolayer is subjected to a shear stress of 8 dyne/cm2. N=6. Error bars
represent SE. * indicates p-value < 0.05.
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5-2 Attachment Results
The attachment of the different MDA-MB-231 cell lines is shown in Figure 5-3. At a
shear stress of 0.25 dyne/cm2, the control cell line had significantly greater attachment
than the two knocked down cell lines. This indicates that CD151 and β1 effect initial
attachment. With attachment studies it is postulated cancer cells do not have a long
enough residence time to invoke a response would overcome the loss of CD151 and β1
the adhesion proteins. It is also possible that since one of the proteins is absent, the two
cannot associate to aid in adhesion. These results are the first that have examined how
these proteins effect initial adhesion as static studies can only determine the effects on
firm adhesion and in vivo studies do not have the capabilities to separate the two different
types of adhesion into different studies. Chen et al. found that β1 kd MDA-MB-231 cells
were less adhesive to an endothelial monolayer than the control MDA-MB-231 cells
which is in agreement to the detachment experiments at 8 dyne/cm2 and the attachment
experiments reported here[54].
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Figure 5-3: Attachment of cancer cells to an endothelial monolayer the cancer cells
are introduced at a flowrate that produces a shear stress of 0.25 dyne/cm2 on the
endothelial monolayer. N=6. Error bars represent SE. * indicates p-value < 0.05.
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5-3 Random Migration Results
Transwell assays were performed to determine how CD151 and β1 effected random
migration on different surfaces. Four different surface conditions were examined and the
results were shown here in Figure 5-4. When cancer cells were seeded directly on gelatin,
the control cancer cells migrated less than the CD151 kd and the β1 kd cancer cell lines.
When a confluent monolayer of endothelial cells were introduced on the control cancer
cells migrated less than the β1 kd cells. However, there was no significant difference
between the migration of the control cells and the CD151 kd cells. When cancer cells
were placed directly onto basement membrane extract, the migration for all cell lines
was statistically different with the control cells migrating the least and the CD151 kd
cells migrating the most. When an endothelial cell monolayer was introduced on the
basement membrane extract, there was no statistical difference in migration flux.
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Figure 5-4: Random migration flux of cancer cell through a 0.4 μm pore under
various conditions. N=12. Error bars represent SE. * indicates p-value < 0.05.
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5-4 Discussion
In the detachment studies, there was no significant difference in the detachment of the kd
cell lines from an endothelial monolayer than the control at a low shear stress of 2
dyne/cm2. However, at a higher shear stress of 8 dyne/cm2, the kd cells detached
significantly more than the control cells. This indicates that CD151 and β1 are crucial for
firm adhesion at high shear stress such as those found in the arterial system but not at low
shear stresses. Attachment studies determined that both CD151 and β1 play a significant
role in initial adhesion since the attachment to the endothelial monolayer was
significantly impaired when CD151 and β1 is knocked down. The role of CD151 in
adhesion to an endothelial monolayer was confirmed by Takeda et al. who demonstrated
that cancer cells adhered less to CD151-null MLECs. These studies were performed in a
static well plate so direct comparisons cannot be made only trends can be observed[43].
Chen et a. confirmed that β1 affected adhesion to a planar HUVEC monolayer under
shear flow. It was determined that β1 kd cells had significantly decreased adhesion[54].
Ad stated previously, CD151 and β1 tightly associate to form complexes that are stable
under even extreme conditions such as exposure to Triton-X. When either protein is
absent, this complex cannot be formed which could be the cause in decrease in adhesion.
In the migration studies, both kd cell lines migrated more than the control cells when
seeded directly on the matrix. When endothelial cells were seeded on the gelatin matrix
before the introduction of cancer cells, only the β1 migrated more than the control cells,
and when endothelial cells were seeded on the basement membrane extract, there was no
difference in migration. As described earlier, the cell’s ability to migrate depends on the
adhesive forces. CD151 and β1 interact to aid in laminin binding and binding to different
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types of collagen. Since basement membrane extract contains both laminin and collagen
IV and gelatin is a collagen based compound, the control cells should adhere more to
these compounds to a greater extent than the kd cells which would decrease the migration
rate of the control cells. When Deng et al. examined migration of MCF-10A cells through
an endothelial monolayer when no chemoattractant was present, there was not difference
in migration between the control cells and the CD151 kd cells which was in agreement to
what was observed in these studies[44]. Figure 5-5 shows how our data fit into and adds
to current literature.
In conclusion, CD151 and β1 significantly affect firm adhesion of MDA-MB-231 cells to
an endothelial monolayer at high shear stress but not low shear stresses. CD151 and β1
affected the initial adhesion of MDA-MB-231 cells to an endothelial monolayer. When
CD151 and β1 was absent, MDA-MB-231 cells migrated to a greater amount through the
either a gelatin or basement membrane extract matrix.

53

Migration Through
Matrix/Membrane

•

•

•
54
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Figure 5-5: Summary of our results written in red and how it fits in with other research in the same area of interest.
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5-5 Future Work
5-5.1 Determining the Effects of Shear on Extravasation
The model that was used to study migration here was a static transwell assay. To gain a
more comprehensive view on the effects of CD151 and β1 on tumor cell extravasation, a
model that allows for the cells to be under shear stress needs to be utilized. An example
of this type of model are microfluidic models such as those proposed by Jeon et al. and
Zhang et al[8, 69]. As noted with the detachment studies reported here, cells will detach
to different extents under different shear stresses. It is possible that when subjected to
shear stress, a different pattern in migration will occur than that in the transwell assay.
5-5.2 Investigating Alternate Cancer Cell Lines
The chosen cell line for these studies was MDA-MB-231. This breast cancer cell line is
referred to as a triple negative phenotype because it does not express ERα, PR, and
HER2. It has the classification of Caudin-low[70]. This cell line is one of the most
commonly used metastatic breast cancer cell lines for in vitro studies. It is possible that
an underlying characteristic of the MDA-MB-231 cell line is effects how the cancer cells
adhere and migrate when CD151 or β1 is absent. Therefore, these studies should be
repeated with alternate cell lines. One option would be to look at a breast cancer cell line
that is not triple negative for example MDA-MB-453 which does not express ERα or PR
but is positive for HER2. Another would be to examine the effects on a different cancer
such as the hepatocellular carcinoma cell line HCCLM3 which has been shown to have
very high expression of CD151.
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5-5.3 Investigating Alternate Endothelial Cell Lines
HUVECs, as denoted by the name, are an endothelial cell line harvested from the
umbilical cord vein. Endothelial cells will take on different morphologies and
configuration depending on their location in the circulation meaning that vein, arterial,
and microvascular cells all have different morphologies. For example, there are
intercellular gaps in arterial and venous segments but not in capillary segments. This
indicates that cells would adhere and extravasate different in these sections of the
circulatory system[71]. A microvascular endothelial cell line such as Human Dermal
Microvascular Endothelial Cells, HMVEC, and an arterial cell line such as Human
Pulmonary Artery Endothelial cells, HPAEC, should be utilized in repeated experiments
to determine if the effects of CD151 and β1 on adhesion and migration vary depending on
endothelial cell line.
5-5.4 Investigating the Effects of Smooth Muscle Cells
In the migration studies described here, it was determined how the matrix and how a
monolayer of endothelial cells affected migration. However, the endothelial cells of the
veins and arteries are surrounded by smooth muscle cells which would add another layer
of resistance and could greatly affect how cells extravasate. Therefore, transwell studies
need to be repeated using a smooth muscle cell line such as Primary Aortic Smooth
Muscle cells.
5-5.5 Determining the Threshold of Detachment
At 2 dyne/cm2 there was no significance in detachment. However, at a shear stress of 8
dyne/cm2, there the knocked down cells detached significantly more than the control
cells. These shear stresses had been chosen as representative shear stresses of the venous
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and arterial circulation. The shear stress in the venous circulation can range up to 4
dyne/cm2, and the arterial circulation can range as low as 4 dyne/cm2. Due to a gap of 6
dyne/cm2, it is unknown at what threshold the shear stress is high enough to cause
significant detachment. Ideally, the next set of experiments should be conducted at 4
dyne/cm2 since this is the overlapping shear stress for the venous and arterial circulation.
5-5.6 Determining the Effects of Cell Cycle on Metastasis
In many of the transwell studies performed here, there were clusters of multiple cells.
This indicates that either the cells had migrated through as a cluster, clustered after
migration, or had divided and multiplied after migrating. As discussed earlier, since the
imaging is performed in the plane parallel to migration, it is impossible to determine
which is occurring using transwell assays alone. However, to give further insight on if the
cells are multiplying, one of two modifications can be made to these studies. The first is
to decrease the amount of time that the cells are allowed to migrate. For example, one
common shorter endpoint for transwell assays is four hours. This would give the cells
less time to undergo the cell cycle. The second option would be to synchronize the cells
by culturing them in serum free media for 24 hours prior to seeding in the transwells.
This would ensure that all cells are on the same phase of the cell cycle at the beginning of
the experiments. Previous studies have shown that nearly all cells that adhere to a vessel
wall are in the G1 phase while the cells that migrate across the vessel wall are in the G1/S
transition indicating that cell cycle does play a role in these processes[72].
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5-5.7 Alternative Transwell Assays
Depending on how the transwell assay is preform, these studies can answer many
different questions. In the studies that have been described here, we determined how
CD151 and β1 effected random migration. However, to determine how these proteins
effect directed migration, studies need to be performed in which serum free media is
placed inside of the insert and media containing FBS is placed inside of the well. This
concentration difference will act to polarize the cells and enhance migration.
Alternative migration studies cold also be performed in which the HUVECs are seeded
on the opposite side of the membrane. This would mimic the configuration of
intravasation rather than extravasation.
5-5.8 Determining the Effects of shRNA Gene Silencing vs Antibodies
There are two ways to negate the effects of a protein in a process. The first is through
gene silencing. As mentioned earlier, shRNA was used to knock down the genes for
CD151 and β1 in the studies that were described there. There is also the method of siRNA
(small interfacing RNA) to knock down genes. These methods both work by degrading
the target mRNA (messenger RNA). The second method to negate the effects of a protein
is through an antibody. An antibody will physically bind to the protein of interest and
physically prevent the protein from interacting with its environment. These methods will
affect the cell and its adhesion differently. For example, the loss of a protein could cause
structural differences in the cell while the antibody could also block other proteins that
are not the targeted protein. Doing comparison studies would determine if CD151 and β1
were the cause of decreased adhesion or if it was due to an unknown side effect of the
gene silencing.
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List of Abbreviations
ATCC

American Type Cell Culture

BME

Basement Membrane Extract

CAM

Chick Chorioallantoic Membrane

CD151

Cluster of Differentiation 151

CXCL12

Chemokine (C-X-C motif) ligand 12

CXCR4

chemokine receptor type 4

CXCR7

chemokine receptor type 7

DMEM

Dulbecco’s Modified Eagle Medium

DiI

1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate

DiO

3,3'-Dioctadecyloxacarbocyanine Perchlorate

EBM

Endothelial Growth Basal Medium

EDTA

Trypsin Ethylenediaminetetraacid Acid

EGF

Epidermal Growth Factor

EGM-2

Endothelial Growth Medium 2

EMT

Epithelial to Mesenchymal Transition

FBS

Fetal Bovine Serum

GFP

Green Florescent Protein

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HGF

Hepatocyte Growth Factor

HUVEC

Human Umbicial Vein Endothelial Cell

ICAM-1

Intercellular Adhesion Molecule

IgG

Immunoglubulin G

LLC

Lewis lung carcinoma

MLEC

Mouse lung endothelial cells

mRNA

Messanger RNA

PBS

Phosphate-buffered saline

PECAM-1

Platelet endothelial cell adhesion molecule

PMA

phorbol 12-myristate 13-acetate
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shRNA

small/short hairpin RNA

siRNA

small interfacing RNA

TGF-β

Transforming Growth Factor

TNF-α

Tumor Necrosis Factor-α

TNS

Trypsin Neutralizing Solution
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